首页|尼可地尔联合硝酸酯类药物治疗微血管心绞痛的临床疗效及对患者心绞痛发作的影响

尼可地尔联合硝酸酯类药物治疗微血管心绞痛的临床疗效及对患者心绞痛发作的影响

扫码查看
目的 探讨联用尼可地尔及硝酸酯类药物治疗微血管心绞痛的疗效.方法 选取 2021 年 6 月—2023 年 6月我院收治的 84 例微血管心绞痛患者为研究对象,按随机数字表法将其分为对照组与观察组,各 42 例.对照组采用单硝酸异山梨酯治疗,观察组在对照组的基础上加用尼可地尔治疗,两组均持续治疗 8 周.比较两组临床疗效、心绞痛发作情况、血管内皮功能、心电图指标及安全性.结果 观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组心绞痛发作次数为(3.44±0.42)次/周,少于对照组的(5.37±0.85)次/周,持续时间为(2.04±0.28)min,短于对照组的(3.65±0.37)min,组间差异有统计学意义(P<0.05);观察组一氧化氮水平为(46.89±4.25)μmol/L,高于对照组的(41.33±4.15)μmol/L,内皮素-1 水平为(40.15±4.12)ng/L,低于对照组的(46.38±4.37)ng/L,组间差异有统计学意义(P<0.05);观察组运动平板试验总运动时间、ST段压低 0.1 mV时间分别为(8.96±0.87)min、(7.46±0.75)min,均长于对照组的(6.85±0.79)min、(5.87±0.67)min,ST段最大压低幅度为(0.54±0.11)mV,小于对照组的(0.78±0.13)mV,组间差异有统计学意义(P<0.05).两组均无明显不良反应发生.结论 尼可地尔联合硝酸酯类药物可提高微血管心绞痛治疗效果,减轻血管内皮功能障碍,减少心绞痛发作,安全可靠.
Clinical Efficacy of Nicodil Combined with Nitrates in the Treatment of Microvascular Angina Pectoris and Its Influence on the Onset of Angina Pectoris
Objective To investigate the effect of combination of nicodil and nitrates in the treatment of microvascular angina pectoris.Methods A total of 84 patients with microvascular angina pectoris treated in our hospital from June 2021 to June 2023 were selected as the study objects,and randomly divided into a control group and an observation groupaccording to random number table method,with 42 cases in each group.The control group was treated with isosorbide mononitrate,and the observation group was treated with nicodil on the basis of the control group and both groups were treated for 8 weeks.The clinical efficacy,angina pectoris attack,vascular endothelial function,electrocardiog index and safety of the two groups were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).After treatment,the frequency of angina pectoris attacks in the observation group was(3.44±0.42)times/week,which was less than(5.37±0.85)times/week in the control group,and the duration was(2.04±0.28)min,which was shorter than(3.65±0.37)min in the control group,the differences between the groups were statistically significant(P<0.05);the level of nitric oxide in the observation group was(46.89±4.25)μmol/L,higher than(41.33±4.15)μmol/L in the control group,and the level of endothelin-1 was(40.15±4.12)ng/L,endothelin-1 which was lower than(46.38±4.37)ng/L in the control group,the differences between the groups were statistically significant(P<0.05);the total motion time and ST segment depression 0.1 mV in the observation group were(8.96±0.87)min and(7.46±0.75)min,respectively,which were both longer than(6.85±0.79)min and(5.87±0.67)min in the control group,the maximum ST segment depression was(0.54±0.11)mV,which was lower than(0.78±0.13)mV of control group,and the differences between the groups were statistically significant(P<0.05).No obvious adverse reactions occurred in both groups.Conclusion Nicordil combined with nitrates can improve the efficacy of microvascular angina pectoris,relieve vascular endothelial dysfunction,reduce angina pectoris attack,and is safe and reliable.

Microvascular angina pectorisNicordilVascular endothelial functionAngina pectoris attackSafety

赵志同

展开 >

金乡县人民医院心内科,山东济宁 272000

微血管心绞痛 尼可地尔 血管内皮功能 心绞痛发作 安全性

2024

反射疗法与康复医学

反射疗法与康复医学

ISSN:
年,卷(期):2024.5(17)